Vicore Pharma Holding AB (publ) (STO:VICO)

Vicore Pharma Holding AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-370.92	-168.63	-310.94	-288.42	-296.48	-146.86
Depreciation & Amortization	0.56	2.24	3.42	3.61	3.6	3.54
Loss (Gain) From Sale of Assets	-	-	-	2	-	-
Asset Writedown & Restructuring Costs	-	-	62.55	-	-	-
Other Operating Activities	41.26	3.28	6.03	3.83	0.64	0.71
Change in Accounts Receivable	-28.99	-35.6	-4.28	-1.6	-0.34	-3.87
Change in Accounts Payable	27.06	33.77	-6.36	-19.34	27.41	26.55
Operating Cash Flow	-331.04	-164.95	-249.58	-299.92	-265.17	-119.94
Sale (Purchase) of Intangibles	-	-	-	-3	-	-3
Investment in Securities	-478.88	149.04	-144.46	77	-7	7
Investing Cash Flow	-480.29	149.04	-144.46	74	-7	4
Issuance of Common Stock	882.15	882.14	500.41	200	336	187.55
Other Financing Activities	-48.08	-48.08	-29.55	-12.96	-17.82	-10.58
Financing Cash Flow	834.07	834.06	470.86	187.04	318.18	176.97
Foreign Exchange Rate Adjustments	-29.8	4.23	-	1.48	-0.43	-
Net Cash Flow	-7.05	822.38	76.82	-37.4	45.58	61.03
Free Cash Flow	-331.04	-164.95	-249.58	-299.92	-265.17	-119.94
Free Cash Flow Margin	-4276.40%	-150.85%	-	-	-	-
Free Cash Flow Per Share	-1.67	-1.21	-2.58	-4.15	-3.81	-2.21
Cash Interest Paid	0.04	0.01	0	0.01	0.01	0.01
Levered Free Cash Flow	-240.82	-111.57	-200.41	-195.17	-160.92	-71.86
Unlevered Free Cash Flow	-215.25	-111.56	-200.41	-195.16	-160.92	-71.86
Change in Working Capital	-1.94	-1.84	-10.65	-20.94	27.07	22.68

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.